Baxter International Inc. (NYSE:BAX) has alerted health care professionals to a looming shortage of ifosfamide-based cancer therapies across the European Union, following a technical disruption at a contract manufacturing site.

• Baxter International stock is showing downward bias. Where is BAX stock headed?

The company said the supply constraint, which affects products marketed as Holoxan, Tronoxal and Mitoxana, is expected to persist until the first quarter of 2027, prompting allocation controls and treatment prioritization measures.

Manufacturing Disruption Triggers EU-Wide Supply Crunch

The shortage stems from a technical issue at a third-party manufacturing facility that disrupted production planning, inventory systems and product release cycles.

The site was also undergoing corrective actions after a regulatory inspection, compounding the disruption.

Baxter, the primary supplier of ifosfamide in the EU, said manufacturing ...